Exposure of R6/2 mice in an enriched environment augments P42 therapy efficacy on Huntington ? s disease progression

NEUROPHARMACOLOGY

卷:186

Article

Couly, Simon^1,3  Carles, Allison¹  Denus, Morgane¹  Benigno-Anton, Lorraine²  Maschat, Florence¹  Maurice, Tangui¹ 

[1] Univ Montpellier, MMDN, EPHE, INSERM, Montpellier, France

[2] Medesis Pharma, Baillargues, France

[3] NIDA, Cellular Pathobiol Sect, Integrat Neurosci Res Branch, Intramural Res Program,NIH, 333 Cassell Dr, Baltimore, MD 21224 USA

关键词: Huntington?s disease;    R6;    2 mice;    P42 peptide;    Hamlet test;    Environmental enrichment;    BDNF;   

DOI  :  10.1016/j.neuropharm.2021.108467

来源: Elsevier

【 摘 要 】

Huntington?s disease (HD) is due to a mutation in the gene encoding for Huntingtin protein generating polyQ domain extension. Mutant Htt (mHtt) leads to important dysfunction of the BDNF/TrkB signaling. We previously described the 23aa Htt fragment P42, that attenuated the pathological phenotypes induced by mHtt. We reported that, in the R6/2 mouse model of HD, P42 rescued striatal TrkB level but marginally increased cortical BDNF. In the present study, our aim was to address P42 neuroprotection in presence of an external input of BDNF. We combined P42 administration with environmental enrichment (EE), induced by training in the Hamlet test. We examined the consequences of P42 + EE combination on different phenotypes in R6/2 HD mice: motor and cognitive performances, recorded at early and late pathological stages, and analyzed aggregated mHtt and BDNF levels in forebrain structures. Hamlet exploration (i.e., entries in Run, Hide, Eat, Drink and Interact houses) was gradually impaired in R6/2 mice, but maintained by P42 treatment until week 8. Topographic memory alteration measured at week 7 was attenuated by P42. Motor performances (rotarod) were significantly ameliorated by the P42 + EE combination until late stage (week 12). The P42 + EE combination also significantly decreased aggregated Htt levels in the hippocampus, striatum and cortex, and increased BDNF levels in the cortex and striatum. We concluded that combination between P42 treatment, known to increase TrkB striatal expression, and a BDNF-enhancing therapy such as EE efficiently delayed HD pathology in R6/2 mice. Use of dual therapies might be a pertinent strategy to fight neurodegeneration in HD.

【 授权许可】

Free